Can a tiny beacon make prostate radiation safer?
NCT ID NCT03254420
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a device called Calypso, which tracks the prostate's position in real time during radiation, can reduce long-term side effects compared to standard image-guided radiation. 74 men with low- or intermediate-risk prostate cancer took part. The goal is to see if more precise targeting leads to fewer bowel and bladder problems after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Calypso beacon implant and moderate hypofractionation radiotherapy
What this could lead to
If successful, this could show that using the Calypso tracking system reduces long-term side effects from radiation for prostate cancer.
What could go wrong
This is a small, early-phase study (74 patients) and may not prove a clear benefit. The technology adds an extra implant procedure, which carries its own risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institut regional du Cancer - Val d Aurelle
Montpellier, 34298, France